Daraxonrasib Pill Shows Tumour Shrinkage in Pancreatic Cancer Trial, Researchers Say

pancreatic cancer pill: an experimental tablet called daraxonrasib shrank or stopped growth of tumours in most patients in an early trial, and the cancer became undetectable in one in 12 people given the drug. Doctors say it is not yet a cure, but the results offer encouraging hope of more time.

Pancreatic cancer pill, Digimart Global: A pill that can shrink and potentially eliminate pancreatic tumours is being described as the biggest breakthrough in treatment for the disease in decades. The drug, daraxonrasib, was tested in a trial of 61 patients who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

In the trial, the cancer became undetectable in one in 12 patients given the drug, and tumours stopped growing in almost all participants. Tumours stopped growing in 90% of patients, just over 60% had their tumours shrink or disappear, and about 8% had tumours that became undetectable on CT scans.

Doctors stress that the pill cannot yet be considered a cure, and it is not known how long it can keep the disease under control. Participants were followed for an average of a year and a half, and some did not see their cancer return during that period.

Longer studies will be needed to determine whether any cancers can go into remission.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. He described the results as the closest to a cure he has seen, and said he had never seen so many tumours disappear in patients whose cancer had spread.

The early figures also suggest a benefit in survival. A year after starting treatment, 76.6% of patients were alive, compared with the usual 40-45% of patients given chemotherapy alone.

Dr Park said the findings point to deeper responses and a near doubling in the duration of disease control, which may eventually lead to longer survival.

Daraxonrasib is a KRAS inhibitor. It works by locking on to and shutting off certain mutations found in most pancreatic cancers, which drive tumour growth.

Because other cancers can carry similar mutations, there are hopes the treatment could be effective against dozens of other cancers.

Michelle Mitchell, chief executive of Cancer Research UK, said more research was needed but described the results as the biggest leap forward in decades for pancreatic cancer patients. She said more trials are needed before the treatment can be assessed for use on the NHS, and noted that pancreatic cancer survival remains very low.

Half of people diagnosed with the disease die within three months, and only about 3% survive five years when it has spread to other organs.

Freya Sullivan

Freya Sullivan covers British politics, parliamentary affairs, government policies, and economic developments. Her reporting explores major decisions, business trends, and public policy issues shaping the United Kingdom's political and economic landscape.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global